SynthesisEuropean journal of clinical pharmacology2026
Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus Disease (COVID-19), which is caused by SARS-CoV-2 virus, led to a worldwide pandemic in late 2019, thus challenged the healthcare infrastructure across the world, creating an urgent need for the development of effective antiviral medications to handle its spread and evolving strains.
objectiveThis Meta-Analysis aims to investigate the overall efficacy and safety of Ensitrelvir.
methodsWe conducted a systematic review and meta-analysis, according to PRISMA guidelines, searching web databases for relevant literature. We limited our eligibility to randomized clinical trials involving mild-to-moderate COVID-19 patients.
resultsOur study included four randomized controlled trials involving a total of 2,890 patients. For patients with mild-to-moderate Covid-19, treatment with Ensitrelvir (125 mg or 250 mg) was associated with significantly improved outcomes compared to placebo across several metrics: higher viral clearance was observed for 125 mg [MD = - 37.74, P < 0.00001] and 250 mg [MD = - 35.02, P < 0.00001]; greater reductions in viral RNA were achieved by 125 mg [MD = -1.41, P < 0.00001] and 250 mg [MD = -1.37, P < 0.00001]; and a significantly lower proportion of patients maintained a positive viral titer at 125 mg [RR 0.08, P < 0.00001, I
conclusionThis systematic review and meta-analysis support Ensitrelvir efficacy and safety in promoting rapid viral clearance and greater reduction in viral RNA in mild-to-moderate or asymptomatic COVID-19 patients, justifying its integration into outpatient treatment protocols while emphasizing the need for further large-scale, variant-inclusive studies to validate and extend these findings. REGISTRATION: PROSPERO (CRD420251030953).
Indexed as
Identifiers
42371105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.